The World Within US
As a child, Ami Bhatt, MD, PhD (assistant professor, Hematology, and assistant professor, Genetics), found herself drawn to science.
Professor Emeritus Dr. Stanley Schrier on his years with the Stanford Division of Hematology
The Schrier Fellow Scholar Award (SFSA) was created to honor the outstanding career and achievements of Dr. Stanley Schier.
Message from the Chief
Welcome to the Stanford Division of Hematology, a dynamic center for basic and translational research, clinical trials, patient care, and teaching. Our physicians, scientists, staff, and trainees collaborate to advance the understanding and treatment of hematologic disorders, all with the goal of improving outcomes for patients with these diseases. In pursuit of this objective, we engage with the broader Stanford community to bring innovation to our efforts.
Over the last 20 years, multiple novel therapies have resulted in significant clinical advances for hematologic diseases, and Stanford investigators have played key roles in their development, including imatinib for CML, ibrutinib for CLL, midostaurin for mast cell disease, and many others. Our clinicians have expertise in a broad range of hematologic disorders including acute and chronic leukemias, myeloproliferative neoplasms, myelodysplastic syndromes, multiple myeloma, amyloidosis, thrombotic diseases, coagulation disorders, and general hematology. The basic and translational research efforts of the division have led to fundamental discoveries in areas as diverse as leukemia & stem cells, genomics, thrombosis, telomere & cancer biology, and the microbiome. Our passionate faculty members have mentored and trained leaders in the field of hematology and are committed to attract the next generation of leading physicians and research scientists. We invite you to learn more about us through our website.
We are about our patients.
The miracle of a patient's recovery
A 28-year-old woman has a miscarriage while on vacation in Mexico. When she goes to the doctor, a nightmare begins. She ends up spending the next five years in and out of hospitals. At one point, she’s told she’s going to die. She takes chemotherapy, sees a naturopath, sees doctors in her native Ukiah and at Stanford, even goes to Philadelphia and Boston to see experts on the disease. They all agree that nothing can be done.